JP7355976B2 - Cd70と結合する抗体、その調製および使用 - Google Patents
Cd70と結合する抗体、その調製および使用 Download PDFInfo
- Publication number
- JP7355976B2 JP7355976B2 JP2022015259A JP2022015259A JP7355976B2 JP 7355976 B2 JP7355976 B2 JP 7355976B2 JP 2022015259 A JP2022015259 A JP 2022015259A JP 2022015259 A JP2022015259 A JP 2022015259A JP 7355976 B2 JP7355976 B2 JP 7355976B2
- Authority
- JP
- Japan
- Prior art keywords
- antibody
- cells
- antigen
- cancer
- chain variable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 101000934356 Homo sapiens CD70 antigen Proteins 0.000 title claims description 85
- 102100025221 CD70 antigen Human genes 0.000 title claims description 76
- 238000002360 preparation method Methods 0.000 title description 4
- 210000004027 cell Anatomy 0.000 claims description 141
- 230000027455 binding Effects 0.000 claims description 102
- 239000000427 antigen Substances 0.000 claims description 61
- 108091007433 antigens Proteins 0.000 claims description 61
- 102000036639 antigens Human genes 0.000 claims description 61
- 206010028980 Neoplasm Diseases 0.000 claims description 45
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 27
- 239000008194 pharmaceutical composition Substances 0.000 claims description 20
- 201000011510 cancer Diseases 0.000 claims description 19
- 150000007523 nucleic acids Chemical class 0.000 claims description 18
- 239000013604 expression vector Substances 0.000 claims description 17
- 102000039446 nucleic acids Human genes 0.000 claims description 17
- 108020004707 nucleic acids Proteins 0.000 claims description 17
- 208000017604 Hodgkin disease Diseases 0.000 claims description 9
- 208000021519 Hodgkin lymphoma Diseases 0.000 claims description 9
- 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 9
- 208000015914 Non-Hodgkin lymphomas Diseases 0.000 claims description 8
- 241001529936 Murinae Species 0.000 claims description 7
- 208000006265 Renal cell carcinoma Diseases 0.000 claims description 7
- 239000003937 drug carrier Substances 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 6
- 208000029742 colonic neoplasm Diseases 0.000 claims description 6
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims description 6
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims description 6
- 206010006187 Breast cancer Diseases 0.000 claims description 5
- 208000026310 Breast neoplasm Diseases 0.000 claims description 5
- 208000011691 Burkitt lymphomas Diseases 0.000 claims description 5
- 241000701044 Human gammaherpesvirus 4 Species 0.000 claims description 5
- 206010033128 Ovarian cancer Diseases 0.000 claims description 5
- 206010061535 Ovarian neoplasm Diseases 0.000 claims description 5
- 208000005017 glioblastoma Diseases 0.000 claims description 5
- 201000001441 melanoma Diseases 0.000 claims description 5
- 208000004736 B-Cell Leukemia Diseases 0.000 claims description 4
- 208000003174 Brain Neoplasms Diseases 0.000 claims description 4
- 206010009944 Colon cancer Diseases 0.000 claims description 4
- 208000031671 Large B-Cell Diffuse Lymphoma Diseases 0.000 claims description 4
- 206010025323 Lymphomas Diseases 0.000 claims description 4
- 208000025205 Mantle-Cell Lymphoma Diseases 0.000 claims description 4
- 208000034578 Multiple myelomas Diseases 0.000 claims description 4
- 206010061306 Nasopharyngeal cancer Diseases 0.000 claims description 4
- 208000000102 Squamous Cell Carcinoma of Head and Neck Diseases 0.000 claims description 4
- 208000033559 Waldenström macroglobulinemia Diseases 0.000 claims description 4
- 210000003169 central nervous system Anatomy 0.000 claims description 4
- 206010012818 diffuse large B-cell lymphoma Diseases 0.000 claims description 4
- 201000003444 follicular lymphoma Diseases 0.000 claims description 4
- 201000000459 head and neck squamous cell carcinoma Diseases 0.000 claims description 4
- 201000008968 osteosarcoma Diseases 0.000 claims description 4
- 201000005825 prostate adenocarcinoma Diseases 0.000 claims description 4
- 208000008839 Kidney Neoplasms Diseases 0.000 claims description 3
- 201000003793 Myelodysplastic syndrome Diseases 0.000 claims description 3
- 208000001894 Nasopharyngeal Neoplasms Diseases 0.000 claims description 3
- 206010038389 Renal cancer Diseases 0.000 claims description 3
- 208000031673 T-Cell Cutaneous Lymphoma Diseases 0.000 claims description 3
- 201000007455 central nervous system cancer Diseases 0.000 claims description 3
- 201000010897 colon adenocarcinoma Diseases 0.000 claims description 3
- 201000007241 cutaneous T cell lymphoma Diseases 0.000 claims description 3
- 201000010982 kidney cancer Diseases 0.000 claims description 3
- 201000005962 mycosis fungoides Diseases 0.000 claims description 3
- 208000025638 primary cutaneous T-cell non-Hodgkin lymphoma Diseases 0.000 claims description 3
- 208000000728 Thymus Neoplasms Diseases 0.000 claims 1
- LTFUAYRGVLQXKC-NTUHNPAUSA-N 1-tert-butyl-3-[(E)-(2,4-dihydroxyphenyl)methylideneamino]thiourea Chemical compound CC(C)(C)NC(=S)N\N=C\c1ccc(O)cc1O LTFUAYRGVLQXKC-NTUHNPAUSA-N 0.000 description 65
- 108090000623 proteins and genes Proteins 0.000 description 43
- 101000868279 Homo sapiens Leukocyte surface antigen CD47 Proteins 0.000 description 37
- 102100032913 Leukocyte surface antigen CD47 Human genes 0.000 description 37
- 239000000203 mixture Substances 0.000 description 31
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 29
- 238000000034 method Methods 0.000 description 28
- 108020004414 DNA Proteins 0.000 description 26
- 239000012634 fragment Substances 0.000 description 24
- 230000005888 antibody-dependent cellular phagocytosis Effects 0.000 description 21
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 description 20
- 108010076504 Protein Sorting Signals Proteins 0.000 description 19
- 230000013595 glycosylation Effects 0.000 description 18
- 238000006206 glycosylation reaction Methods 0.000 description 18
- 230000014509 gene expression Effects 0.000 description 17
- 102000004169 proteins and genes Human genes 0.000 description 17
- 230000004048 modification Effects 0.000 description 16
- 238000012986 modification Methods 0.000 description 16
- 230000004540 complement-dependent cytotoxicity Effects 0.000 description 14
- 210000004602 germ cell Anatomy 0.000 description 13
- 125000000539 amino acid group Chemical group 0.000 description 12
- 239000002609 medium Substances 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 239000013598 vector Substances 0.000 description 12
- 230000035772 mutation Effects 0.000 description 11
- 235000018102 proteins Nutrition 0.000 description 11
- 210000004881 tumor cell Anatomy 0.000 description 11
- 108010019670 Chimeric Antigen Receptors Proteins 0.000 description 10
- 239000013642 negative control Substances 0.000 description 10
- 230000001105 regulatory effect Effects 0.000 description 10
- 102100027207 CD27 antigen Human genes 0.000 description 9
- 101000914511 Homo sapiens CD27 antigen Proteins 0.000 description 9
- 102000053826 human CD70 Human genes 0.000 description 9
- 230000003993 interaction Effects 0.000 description 9
- XJMOSONTPMZWPB-UHFFFAOYSA-M propidium iodide Chemical compound [I-].[I-].C12=CC(N)=CC=C2C2=CC=C(N)C=C2[N+](CCC[N+](C)(CC)CC)=C1C1=CC=CC=C1 XJMOSONTPMZWPB-UHFFFAOYSA-M 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 108020001507 fusion proteins Proteins 0.000 description 8
- 102000037865 fusion proteins Human genes 0.000 description 8
- 108060003951 Immunoglobulin Proteins 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 7
- 210000001744 T-lymphocyte Anatomy 0.000 description 7
- 229940085936 cusatuzumab Drugs 0.000 description 7
- 238000010790 dilution Methods 0.000 description 7
- 239000012895 dilution Substances 0.000 description 7
- 102000018358 immunoglobulin Human genes 0.000 description 7
- 208000027866 inflammatory disease Diseases 0.000 description 7
- 101100112922 Candida albicans CDR3 gene Proteins 0.000 description 6
- 108091026890 Coding region Proteins 0.000 description 6
- 241000699802 Cricetulus griseus Species 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- 210000004978 chinese hamster ovary cell Anatomy 0.000 description 6
- 201000010099 disease Diseases 0.000 description 6
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 6
- 230000000694 effects Effects 0.000 description 6
- 239000002773 nucleotide Substances 0.000 description 6
- 125000003729 nucleotide group Chemical group 0.000 description 6
- 210000001672 ovary Anatomy 0.000 description 6
- 229940124597 therapeutic agent Drugs 0.000 description 6
- 238000012413 Fluorescence activated cell sorting analysis Methods 0.000 description 5
- 229920002873 Polyethylenimine Polymers 0.000 description 5
- 239000004480 active ingredient Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 5
- 239000012636 effector Substances 0.000 description 5
- 230000006870 function Effects 0.000 description 5
- 210000004408 hybridoma Anatomy 0.000 description 5
- 230000007246 mechanism Effects 0.000 description 5
- 230000011664 signaling Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- 230000001225 therapeutic effect Effects 0.000 description 5
- 239000003981 vehicle Substances 0.000 description 5
- 108010054477 Immunoglobulin Fab Fragments Proteins 0.000 description 4
- 108700005091 Immunoglobulin Genes Proteins 0.000 description 4
- 229940024606 amino acid Drugs 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 229940049595 antibody-drug conjugate Drugs 0.000 description 4
- 206010003246 arthritis Diseases 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- 238000005516 engineering process Methods 0.000 description 4
- 210000002865 immune cell Anatomy 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 238000001727 in vivo Methods 0.000 description 4
- 230000002401 inhibitory effect Effects 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 210000002540 macrophage Anatomy 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 241000894007 species Species 0.000 description 4
- 238000003146 transient transfection Methods 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- -1 Cit-Cit Chemical compound 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 102000001706 Immunoglobulin Fab Fragments Human genes 0.000 description 3
- 208000022559 Inflammatory bowel disease Diseases 0.000 description 3
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 3
- 241000124008 Mammalia Species 0.000 description 3
- 108091008874 T cell receptors Proteins 0.000 description 3
- 201000009365 Thymic carcinoma Diseases 0.000 description 3
- 230000000259 anti-tumor effect Effects 0.000 description 3
- 239000000611 antibody drug conjugate Substances 0.000 description 3
- 230000004663 cell proliferation Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000005119 centrifugation Methods 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 230000000295 complement effect Effects 0.000 description 3
- 230000001419 dependent effect Effects 0.000 description 3
- 239000003623 enhancer Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 229940127121 immunoconjugate Drugs 0.000 description 3
- 230000005917 in vivo anti-tumor Effects 0.000 description 3
- 230000006698 induction Effects 0.000 description 3
- 238000001802 infusion Methods 0.000 description 3
- 230000000670 limiting effect Effects 0.000 description 3
- 206010025135 lupus erythematosus Diseases 0.000 description 3
- 210000004698 lymphocyte Anatomy 0.000 description 3
- 238000002703 mutagenesis Methods 0.000 description 3
- 231100000350 mutagenesis Toxicity 0.000 description 3
- 230000003389 potentiating effect Effects 0.000 description 3
- 108020003175 receptors Proteins 0.000 description 3
- 102000005962 receptors Human genes 0.000 description 3
- 238000003259 recombinant expression Methods 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 238000002741 site-directed mutagenesis Methods 0.000 description 3
- 238000012409 standard PCR amplification Methods 0.000 description 3
- 238000010561 standard procedure Methods 0.000 description 3
- 238000007920 subcutaneous administration Methods 0.000 description 3
- 230000008685 targeting Effects 0.000 description 3
- 208000008732 thymoma Diseases 0.000 description 3
- 230000002103 transcriptional effect Effects 0.000 description 3
- 238000001890 transfection Methods 0.000 description 3
- 208000031261 Acute myeloid leukaemia Diseases 0.000 description 2
- DCXYFEDJOCDNAF-UHFFFAOYSA-N Asparagine Natural products OC(=O)C(N)CC(N)=O DCXYFEDJOCDNAF-UHFFFAOYSA-N 0.000 description 2
- 208000023275 Autoimmune disease Diseases 0.000 description 2
- 241000283690 Bos taurus Species 0.000 description 2
- 241000282472 Canis lupus familiaris Species 0.000 description 2
- 108010034753 Complement Membrane Attack Complex Proteins 0.000 description 2
- 241000701022 Cytomegalovirus Species 0.000 description 2
- 102100025137 Early activation antigen CD69 Human genes 0.000 description 2
- 241000283086 Equidae Species 0.000 description 2
- 241000282326 Felis catus Species 0.000 description 2
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 101000934374 Homo sapiens Early activation antigen CD69 Proteins 0.000 description 2
- 101000863873 Homo sapiens Tyrosine-protein phosphatase non-receptor type substrate 1 Proteins 0.000 description 2
- 108010021625 Immunoglobulin Fragments Proteins 0.000 description 2
- 102000008394 Immunoglobulin Fragments Human genes 0.000 description 2
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 2
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 2
- DCXYFEDJOCDNAF-REOHCLBHSA-N L-asparagine Chemical compound OC(=O)[C@@H](N)CC(N)=O DCXYFEDJOCDNAF-REOHCLBHSA-N 0.000 description 2
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 2
- AGPKZVBTJJNPAG-WHFBIAKZSA-N L-isoleucine Chemical compound CC[C@H](C)[C@H](N)C(O)=O AGPKZVBTJJNPAG-WHFBIAKZSA-N 0.000 description 2
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 2
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 2
- KZSNJWFQEVHDMF-BYPYZUCNSA-N L-valine Chemical compound CC(C)[C@H](N)C(O)=O KZSNJWFQEVHDMF-BYPYZUCNSA-N 0.000 description 2
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
- 208000002454 Nasopharyngeal Carcinoma Diseases 0.000 description 2
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 241001494479 Pecora Species 0.000 description 2
- 241000508269 Psidium Species 0.000 description 2
- 108020004511 Recombinant DNA Proteins 0.000 description 2
- 238000011579 SCID mouse model Methods 0.000 description 2
- 230000033540 T cell apoptotic process Effects 0.000 description 2
- 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 2
- 239000004473 Threonine Substances 0.000 description 2
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 2
- 102100029948 Tyrosine-protein phosphatase non-receptor type substrate 1 Human genes 0.000 description 2
- KZSNJWFQEVHDMF-UHFFFAOYSA-N Valine Natural products CC(C)C(N)C(O)=O KZSNJWFQEVHDMF-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 238000007792 addition Methods 0.000 description 2
- 230000000735 allogeneic effect Effects 0.000 description 2
- 210000003719 b-lymphocyte Anatomy 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 150000001720 carbohydrates Chemical class 0.000 description 2
- 230000004154 complement system Effects 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 2
- 230000009089 cytolysis Effects 0.000 description 2
- 231100000599 cytotoxic agent Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 239000002619 cytotoxin Substances 0.000 description 2
- 238000012217 deletion Methods 0.000 description 2
- 230000037430 deletion Effects 0.000 description 2
- 210000004443 dendritic cell Anatomy 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 2
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 2
- 238000009396 hybridization Methods 0.000 description 2
- 230000007124 immune defense Effects 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 230000005847 immunogenicity Effects 0.000 description 2
- 229940072221 immunoglobulins Drugs 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 230000004068 intracellular signaling Effects 0.000 description 2
- 238000007918 intramuscular administration Methods 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- AGPKZVBTJJNPAG-UHFFFAOYSA-N isoleucine Natural products CCC(C)C(N)C(O)=O AGPKZVBTJJNPAG-UHFFFAOYSA-N 0.000 description 2
- 229960000310 isoleucine Drugs 0.000 description 2
- 239000002502 liposome Substances 0.000 description 2
- 230000036210 malignancy Effects 0.000 description 2
- 210000004962 mammalian cell Anatomy 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 230000001394 metastastic effect Effects 0.000 description 2
- 206010061289 metastatic neoplasm Diseases 0.000 description 2
- 238000001823 molecular biology technique Methods 0.000 description 2
- 201000000050 myeloid neoplasm Diseases 0.000 description 2
- 210000000822 natural killer cell Anatomy 0.000 description 2
- 230000002018 overexpression Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 238000002823 phage display Methods 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 108090000765 processed proteins & peptides Proteins 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000001742 protein purification Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 210000001082 somatic cell Anatomy 0.000 description 2
- 210000000130 stem cell Anatomy 0.000 description 2
- 238000013268 sustained release Methods 0.000 description 2
- 238000002560 therapeutic procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000013518 transcription Methods 0.000 description 2
- 230000035897 transcription Effects 0.000 description 2
- 238000013519 translation Methods 0.000 description 2
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 2
- 239000004474 valine Substances 0.000 description 2
- 230000003612 virological effect Effects 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- AGGWFDNPHKLBBV-YUMQZZPRSA-N (2s)-2-[[(2s)-2-amino-3-methylbutanoyl]amino]-5-(carbamoylamino)pentanoic acid Chemical group CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCNC(N)=O AGGWFDNPHKLBBV-YUMQZZPRSA-N 0.000 description 1
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 description 1
- 206010069754 Acquired gene mutation Diseases 0.000 description 1
- ZIBWKCRKNFYTPT-ZKWXMUAHSA-N Ala-Asn-Val Chemical compound [H]N[C@@H](C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C(C)C)C(O)=O ZIBWKCRKNFYTPT-ZKWXMUAHSA-N 0.000 description 1
- LIWMQSWFLXEGMA-WDSKDSINSA-N Ala-Val Chemical compound CC(C)[C@@H](C(O)=O)NC(=O)[C@H](C)N LIWMQSWFLXEGMA-WDSKDSINSA-N 0.000 description 1
- 239000004475 Arginine Substances 0.000 description 1
- 208000036170 B-Cell Marginal Zone Lymphoma Diseases 0.000 description 1
- 208000010839 B-cell chronic lymphocytic leukemia Diseases 0.000 description 1
- 208000003950 B-cell lymphoma Diseases 0.000 description 1
- 230000003844 B-cell-activation Effects 0.000 description 1
- 108010092574 CD69 antigen Proteins 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 1
- 206010052360 Colorectal adenocarcinoma Diseases 0.000 description 1
- 108010069112 Complement System Proteins Proteins 0.000 description 1
- 102000000989 Complement System Proteins Human genes 0.000 description 1
- 108020004635 Complementary DNA Proteins 0.000 description 1
- 241000938605 Crocodylia Species 0.000 description 1
- 239000004971 Cross linker Substances 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108090000323 DNA Topoisomerases Proteins 0.000 description 1
- 102000003915 DNA Topoisomerases Human genes 0.000 description 1
- 239000012625 DNA intercalator Substances 0.000 description 1
- 239000012626 DNA minor groove binder Substances 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 201000010915 Glioblastoma multiforme Diseases 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 1
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 1
- 102100021519 Hemoglobin subunit beta Human genes 0.000 description 1
- 108091005904 Hemoglobin subunit beta Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101000991061 Homo sapiens MHC class I polypeptide-related sequence B Proteins 0.000 description 1
- 101001109501 Homo sapiens NKG2-D type II integral membrane protein Proteins 0.000 description 1
- 101000914514 Homo sapiens T-cell-specific surface glycoprotein CD28 Proteins 0.000 description 1
- 241000714260 Human T-lymphotropic virus 1 Species 0.000 description 1
- 102000018071 Immunoglobulin Fc Fragments Human genes 0.000 description 1
- 108010091135 Immunoglobulin Fc Fragments Proteins 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 description 1
- QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
- DEFJQIDDEAULHB-IMJSIDKUSA-N L-alanyl-L-alanine Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(O)=O DEFJQIDDEAULHB-IMJSIDKUSA-N 0.000 description 1
- ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- ZDXPYRJPNDTMRX-VKHMYHEASA-N L-glutamine Chemical compound OC(=O)[C@@H](N)CCC(N)=O ZDXPYRJPNDTMRX-VKHMYHEASA-N 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 1
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 1
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 1
- 102100029193 Low affinity immunoglobulin gamma Fc region receptor III-A Human genes 0.000 description 1
- 101710099301 Low affinity immunoglobulin gamma Fc region receptor III-A Proteins 0.000 description 1
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 description 1
- NVGBPTNZLWRQSY-UWVGGRQHSA-N Lys-Lys Chemical compound NCCCC[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN NVGBPTNZLWRQSY-UWVGGRQHSA-N 0.000 description 1
- 239000004472 Lysine Substances 0.000 description 1
- 102100030300 MHC class I polypeptide-related sequence B Human genes 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 101100370002 Mus musculus Tnfsf14 gene Proteins 0.000 description 1
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 description 1
- 102100022680 NKG2-D type II integral membrane protein Human genes 0.000 description 1
- 108091005461 Nucleic proteins Proteins 0.000 description 1
- 241000283973 Oryctolagus cuniculus Species 0.000 description 1
- 102220565401 Peptidyl-prolyl cis-trans isomerase FKBP5_N80A_mutation Human genes 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- 241000276498 Pollachius virens Species 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 229940079156 Proteasome inhibitor Drugs 0.000 description 1
- 108010029485 Protein Isoforms Proteins 0.000 description 1
- 102000001708 Protein Isoforms Human genes 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- 108010003723 Single-Domain Antibodies Proteins 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 102100027213 T-cell-specific surface glycoprotein CD28 Human genes 0.000 description 1
- 102000004142 Trypsin Human genes 0.000 description 1
- 108090000631 Trypsin Proteins 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000007537 Type II DNA Topoisomerases Human genes 0.000 description 1
- 108010046308 Type II DNA Topoisomerases Proteins 0.000 description 1
- 108091005956 Type II transmembrane proteins Proteins 0.000 description 1
- 108090000848 Ubiquitin Proteins 0.000 description 1
- 102000044159 Ubiquitin Human genes 0.000 description 1
- QRZVUAAKNRHEOP-GUBZILKMSA-N Val-Ala-Val Chemical compound [H]N[C@@H](C(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](C(C)C)C(O)=O QRZVUAAKNRHEOP-GUBZILKMSA-N 0.000 description 1
- AEMPCGRFEZTWIF-IHRRRGAJSA-N Val-Leu-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(O)=O AEMPCGRFEZTWIF-IHRRRGAJSA-N 0.000 description 1
- JKHXYJKMNSSFFL-IUCAKERBSA-N Val-Lys Chemical compound CC(C)[C@H](N)C(=O)N[C@H](C(O)=O)CCCCN JKHXYJKMNSSFFL-IUCAKERBSA-N 0.000 description 1
- 241000251539 Vertebrata <Metazoa> Species 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 235000004279 alanine Nutrition 0.000 description 1
- 108010056243 alanylalanine Proteins 0.000 description 1
- 239000002168 alkylating agent Substances 0.000 description 1
- 229940100198 alkylating agent Drugs 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 230000009830 antibody antigen interaction Effects 0.000 description 1
- 210000000612 antigen-presenting cell Anatomy 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000003080 antimitotic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 238000013459 approach Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
- 125000003118 aryl group Chemical group 0.000 description 1
- 235000009582 asparagine Nutrition 0.000 description 1
- 229960001230 asparagine Drugs 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 210000001099 axilla Anatomy 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000008499 blood brain barrier function Effects 0.000 description 1
- 210000001218 blood-brain barrier Anatomy 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 238000012410 cDNA cloning technique Methods 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000003833 cell viability Effects 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 208000032852 chronic lymphocytic leukemia Diseases 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 206010009887 colitis Diseases 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000002648 combination therapy Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 238000010276 construction Methods 0.000 description 1
- 239000000356 contaminant Substances 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000018109 developmental process Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000012377 drug delivery Methods 0.000 description 1
- 238000004520 electroporation Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 238000007667 floating Methods 0.000 description 1
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 125000002446 fucosyl group Chemical group C1([C@@H](O)[C@H](O)[C@H](O)[C@@H](O1)C)* 0.000 description 1
- 238000002825 functional assay Methods 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 238000012637 gene transfection Methods 0.000 description 1
- 238000010353 genetic engineering Methods 0.000 description 1
- 210000001102 germinal center b cell Anatomy 0.000 description 1
- 230000012178 germinal center formation Effects 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000012010 growth Effects 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 230000002489 hematologic effect Effects 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 210000003958 hematopoietic stem cell Anatomy 0.000 description 1
- 229940121372 histone deacetylase inhibitor Drugs 0.000 description 1
- 239000003276 histone deacetylase inhibitor Substances 0.000 description 1
- 239000012642 immune effector Substances 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 230000037451 immune surveillance Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000009169 immunotherapy Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000000099 in vitro assay Methods 0.000 description 1
- 238000005462 in vivo assay Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 238000001361 intraarterial administration Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 238000007912 intraperitoneal administration Methods 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 108010054155 lysyllysine Proteins 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 201000007924 marginal zone B-cell lymphoma Diseases 0.000 description 1
- 208000021937 marginal zone lymphoma Diseases 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 108010082117 matrigel Proteins 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 210000001806 memory b lymphocyte Anatomy 0.000 description 1
- 229930182817 methionine Natural products 0.000 description 1
- 239000010445 mica Substances 0.000 description 1
- 229910052618 mica group Inorganic materials 0.000 description 1
- 239000004530 micro-emulsion Substances 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 201000011216 nasopharynx carcinoma Diseases 0.000 description 1
- 230000030147 nuclear export Effects 0.000 description 1
- 230000006548 oncogenic transformation Effects 0.000 description 1
- 238000011275 oncology therapy Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000003204 osmotic effect Effects 0.000 description 1
- 230000000242 pagocytic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 125000001151 peptidyl group Chemical group 0.000 description 1
- 210000001539 phagocyte Anatomy 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 230000008488 polyadenylation Effects 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000010837 poor prognosis Methods 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 210000001236 prokaryotic cell Anatomy 0.000 description 1
- 239000003207 proteasome inhibitor Substances 0.000 description 1
- 239000012268 protein inhibitor Substances 0.000 description 1
- 229940121649 protein inhibitor Drugs 0.000 description 1
- 230000018883 protein targeting Effects 0.000 description 1
- 238000002708 random mutagenesis Methods 0.000 description 1
- 238000010188 recombinant method Methods 0.000 description 1
- 210000003289 regulatory T cell Anatomy 0.000 description 1
- 230000003248 secreting effect Effects 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- MFBOGIVSZKQAPD-UHFFFAOYSA-M sodium butyrate Chemical compound [Na+].CCCC([O-])=O MFBOGIVSZKQAPD-UHFFFAOYSA-M 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 230000000392 somatic effect Effects 0.000 description 1
- 230000037439 somatic mutation Effects 0.000 description 1
- 238000001228 spectrum Methods 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000009258 tissue cross reactivity Effects 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000014723 transformation of host cell by virus Effects 0.000 description 1
- 238000011830 transgenic mouse model Methods 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000012588 trypsin Substances 0.000 description 1
- 230000004565 tumor cell growth Effects 0.000 description 1
- 102000003390 tumor necrosis factor Human genes 0.000 description 1
- 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 1
- 239000005483 tyrosine kinase inhibitor Substances 0.000 description 1
- 241000701161 unidentified adenovirus Species 0.000 description 1
- 108010073969 valyllysine Proteins 0.000 description 1
- 108700026220 vif Genes Proteins 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0681—Cells of the genital tract; Non-germinal cells from gonads
- C12N5/0682—Cells of the female genital tract, e.g. endometrium; Non-germinal cells from ovaries, e.g. ovarian follicle cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/734—Complement-dependent cytotoxicity [CDC]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/10—Plasmid DNA
- C12N2800/106—Plasmid DNA for vertebrates
- C12N2800/107—Plasmid DNA for vertebrates for mammalian
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Rheumatology (AREA)
- Hematology (AREA)
- Reproductive Health (AREA)
- Cell Biology (AREA)
- Oncology (AREA)
- Physical Education & Sports Medicine (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
Description
本出願は、2021年10月13日に出願された中国特許出願第202111191860.4号明細書に対する優先権を主張するものである。
CD70およびCD27
生分解性、生体適合性ポリマーは、エチレン酢酸ビニル、ポリ無水物、ポリグリコール酸、コラーゲン、ポリオルトエステル、およびポリ乳酸などを使用することができる。例えば、Sustained and Controlled Release Drug Delivery Systems,J.R.Robinson,ed.,Marcel Dekker,Inc.,New York,1978を参照されたい。
実施例1.抗CD70抗体の生成およびヒト化、ならびに抗体発現用ベクターの構築
実施例2.細胞表面CD70に結合した例示的な抗体
実施例3.例示的な抗体によるCD27(ECD)-CD70結合/相互作用の阻害
実施例4.例示的な抗体によるCD27-CD70結合/相互作用の阻害
実施例5.例示的な抗体によるCD70+細胞に対して高い抗体依存性細胞媒介性細胞傷害(ADCC)の誘導
溶解率=(IMM40H、IMM01またはIMM40+IMM01で処理した%PI陽性標的細胞-陰性対照で処理した%PI陽性標的細胞)/(100-陰性対照で処理した%PI陽性標的細胞)*100。
実施例6.例示的な抗体によるCD70+細胞に対して高い抗体依存性細胞貪食(ADCP)の誘導
実施例7.例示的な抗体によるCD70+細胞に対する高い補体依存性細胞傷害(CDC)の誘導
実施例8.例示的な抗体が示した強力なインビボ抗腫瘍活性
表1.D52におけるIMM40Hおよび他の薬剤の抗腫瘍効果
参考文献
A.Agathanggelou,G.Niedobitek,R.Chen,J.Nicholls,W.Yin,L.S.Young,Expression of immune regulatory molecules in Epstein-Barr virus-associated nasopharyngeal carcinomas with prominent lymphoid stroma.Evidence for a functional interaction between epithelial tumor cells and infiltrating lymphoid cells,The American journal of pathology,147(1995)1152.
A.W.Ho,E.Hatjiharissi,B.T.Ciccarelli,A.R.Branagan,Z.R.Hunter,X.Leleu,O.Tournilhac,L.Xu,K.O'Connor,R.J.Manning,CD27-CD70 interactions in the pathogenesis of Waldenstroem macroglobulinemia,Blood,The Journal of the American Society of Hematology,112(2008)4683-4689.
B.F.Israel,M.Gulley,S.Elmore,S.Ferrini,W.-h.Feng,S.C.Kenney,Anti-CD70 antibodies:a potential treatment for EBV+ CD70-expressing lymphomas,Molecular cancer therapeutics,4(2005)2037-2044.
Bobby Kwanghoon Han,Nancy J Olsen,Andrea Bottaro.Semin Arthritis Rheum,The CD27-CD70 pathway and pathogenesis of autoimmune disease.2016 Feb;45(4):496-501
C.L.Law,K.A.Gordon,B.E.Toki,A.K.Yamane,M.A.Hering,C.G.Cerveny,J.M.Petroziello,M.C.Ryan,L.Smith,R.Simon,Lymphocyte activation antigen CD70 expressed by renal cell carcinoma is a potential therapeutic target for anti-CD70 antibody-drug conjugates,Cancer Research,66(2006)2328-2337.
C.Pich,G.Sarrabayrouse,I.Teiti,B.Mariame,P.Rochaix,L.Lamant,G.Favre,V.Maisongrosse,A.-F.Tilkin-Mariame,Melanoma-expressed CD70 is involved in invasion and metastasis,British journal of cancer,114(2016)63-70.
C.Riether,C.M.Schurch,E.D.Buehrer,M.Hinterbrandner,A.-L.Huguenin,S.Hoepner,I.Zlobec,T.Pabst,R.Radpour,A.F.Ochsenbein,CD70/CD27 signaling promotes blast stemness and is a viable therapeutic target in acute myeloid leukemia,Journal of Experimental Medicine,214(2017)359-380.
C.Riether,T.Pabst,S.Hopner,U.Bacher,M.Hinterbrandner,Y.Banz,R.Muller,M.G.Manz,W.H.Gharib,D.Francisco,Targeting CD70 with cusatuzumab eliminates acute myeloid leukemia stem cells in patients treated with hypomethylating agents,Nature medicine,26(2020)1459-1467.
Gardai SJ,McPhillips KA,Frasch SC,Janssen WJ,Starefeldt A,Murphy-Ullrich JE,Bratton DL,Oldenborg PA,Michalak M,Henson PM.Cell-surface calreticulin initiates clearance of viable or apoptotic cells through trans-activation of LRP on the phagocyte.Cell.2005; 123:321-334
Gennaro,ed.,Remington:The Science and Practice of Pharmacy,20th Ed.,Lippincott Williams & Wilkins 2003
H.J.Gruss,M.E.Kadin,2 Pathophysiology of Hodgkin's disease:functional and molecular aspects,Bailliere's clinical haematology,9(1996)417-446.
J.A.McEarchern,L.M.Smith,C.F.McDonagh,K.Klussman,K.A.Gordon,C.A.Morris-Tilden,S.Duniho,M.Ryan,T.E.Boursalian,P.J.Carter,Preclinical characterization of SGN-70,a humanized antibody directed against CD70,Clinical Cancer Research,14(2008)7763-7772.
J.Held-Feindt,R.Mentlein,CD70/CD27 ligand,a member of the TNF family,is expressed in human brain tumors,International journal of cancer,98(2002)352-356.
J.H.Pahl,S.J.Santos,M.L.Kuijjer,G.H.Boerman,L.G.Sand,K.Szuhai,A.Cleton-Jansen,R.M.Egeler,J.V.Bovee,M.W.Schilham,Expression of the immune regulation antigen CD70 in osteosarcoma,Cancer cell international,15(2015)1-9.
J.Jacobs,K.Zwaenepoel,C.Rolfo,J.Van den Bossche,C.Deben,K.Silence,C.Hermans,E.Smits,P.Van Schil,F.Lardon,Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer,Oncotarget,6(2015)13462.
J.R.Robinson,ed.,Sustained and Controlled Release Drug Delivery Systems,Marcel Dekker,Inc.,New York,1978
J.Wischhusen,G.Jung,I.Radovanovic,C.Beier,J.P.Steinbach,A.Rimner,H.Huang,J.B.Schulz,H.Ohgaki,A.Aguzzi,Identification of CD70-mediated apoptosis of immune effector cells as a novel immune escape pathway of human glioblastoma,Cancer research,62(2002)2592-2599.
Lee WY,Weber DA,Laur O,Severson EA,McCall I,Jen RP,Chin AC,Wu T,Gernert KM,Parkos CA..Novel Structural Determinants on SIRPa that Mediate Binding to CD47.J Immunol.2007,179:7741-7750
Lutfi F,Wu L,Sunshine S,Cao X.Targeting the CD27-CD70 Pathway to Improve Outcomes in Both Checkpoint Immunotherapy and Allogeneic Hematopoietic Cell Transplantation.Front Immunol.2021 Sep 22;12:715909.doi:10.3389/fimmu.2021.715909.PMID:34630390; PMCID:PMC8493876.
Obeid M,Panaretakis T,Joza N,Tufi R,Tesniere A,van Endert P,Zitvogel L,Kroemer G.Calreticulin exposure is required for the immunogenicity of gamma-irradiation and UVC lightinduced apoptosis.Cell Death Differ.2007,14:1848-1850
Orr AW,Pedraza CE,Pallero MA,Elzie CA,Goicoechea S,Strickland DK,Murphy-Ullrich JE.Low density lipoprotein receptor-related protein is a calreticulin coreceptor that signals focal adhesion disassembly.J Cell Biol.2003,161:1179-1189
S.Aggarwal,T.He,W.Fitzhugh,K.Rosenthal,B.Field,D.Mesmer,E.Joseloff,S.Ruben,P.Moore,Membrane proteomic analyses of ovarian cancer identifies the immune modulators CD70 and B7-H2 as candidate markers of cisplatin response,in,AACR,2008.
Shields RL,Namenuk AK,Hong K,Meng YG,Rae J,Briggs J,Xie D,Lai J,Stadlen A,Li B,Fox JA,Presta LG.High Resolution Mapping of the Binding Site on Human IgG1 for FcγRI,FcγRII,FcγRIII,and FcRn and Design of IgG1 Variants with Improved Binding to the FcgR.JBC.2001,276:6591-6604
S.M.Lens,P.Drillenburg,B.F.Den Drijver,G.Van Schijndel,S.T.Pals,R.A.Van Lier,M.H.Van Oers,Aberrant expression and reverse signalling of CD70 on malignant B cells,British journal of haematology,106(1999)491-503.
T.Hishima,M.Fukayama,Y.Hayashi,T.Fujii,T.Ooba,N.Funata,M.Koike,CD70 expression in thymic carcinoma,The American journal of surgical pathology,24(2000)742-746.
Vlahopoulos,SA.Aberrant control of NF-κB in cancer permits transcriptional and phenotypic plasticity,to curtail dependence on host tissue:molecular mode.Cancer biology & medicine.2017,14:254-270
Shim H.Bispecific Antibodies and Antibody-Drug Conjugates for Cancer Therapy:Technological Considerations.Biomolecules.2020 Feb 26;10(3):360
Wang S,Chen K,Lei Q,Ma P,Yuan AQ,Zhao Y,Jiang Y,Fang H,Xing S,Fang Y,Jiang N,Miao H,Zhang M,Sun S,Yu Z,Tao W,Zhu Q,Nie Y,Li N.The state of the art of bispecific antibodies for treating human malignancies.EMBO Mol Med.2021 Aug 24:e14291.doi:10.15252/emmm.202114291
Claims (13)
- CD70と結合する単離されたモノクローナル抗体またはその抗原結合部分であって、
i)重鎖可変領域であって、前記重鎖可変領域が、配列番号1、2および3に記載のアミノ酸配列をそれぞれ含む重鎖可変領域CDR-1(HV-CDR1)、HV-CDR2およびHV-CDR3を有する、重鎖可変領域と、
ii)軽鎖可変領域であって、前記軽鎖可変領域が、配列番号4、5および6に記載のアミノ酸配列をそれぞれ含む軽鎖可変領域CDR-1(LV-CDR1)、LV-CDR2およびLV-CDR3を有する、軽鎖可変領域と
を備える、単離されたモノクローナル抗体またはその抗原結合部分。 - 前記重鎖可変領域が、配列番号7または9に対して少なくとも90%または95%の同一性を有するアミノ酸配列を備える、請求項1に記載の単離されたモノクローナル抗体またはその抗原結合部分。
- 前記軽鎖可変領域が、配列番号8または10(X=NまたはX=E)に対して少なくとも90%または95%の同一性を有するアミノ酸配列を備える、請求項1または2に記載の単離されたモノクローナル抗体またはその抗原結合部分。
- 前記重鎖可変領域および軽鎖可変領域が、i)配列番号7および8に対して少なくとも90%または95%の同一性を有するアミノ酸配列をそれぞれ備えるか、ii)配列番号9および10(X=N)に対して少なくとも90%または95%の同一性を有するアミノ酸配列をそれぞれ備えるか、またはiii)配列番号9および10(X=E)に対して少なくとも90%または95%の同一性を有するアミノ酸配列をそれぞれ備える、請求項1から3までのいずれか一項に記載の単離されたモノクローナル抗体またはその抗原結合部分。
- IgG1、IgG2またはIgG4アイソタイプである、請求項1から4までのいずれか一項に記載の単離されたモノクローナル抗体またはその抗原結合部分。
- 配列番号11および12のアミノ酸配列をそれぞれ有する重鎖定常領域および軽鎖定常領域を備える、請求項1から5までのいずれか一項に記載の単離されたモノクローナル抗体またはその抗原結合部分。
- マウスであるか、キメラであるか、またはヒト化されている、請求項1から6までのいずれか一項に記載の単離されたモノクローナル抗体またはその抗原結合部分。
- 請求項1から7までのいずれか一項に記載の単離されたモノクローナル抗体またはその抗原結合部分をコードする核酸分子。
- 請求項8に記載の核酸分子を含む発現ベクター。
- 請求項8に記載の核酸分子または請求項9に記載の発現ベクターを含む宿主細胞。
- 治療有効量の請求項1から7までのいずれか一項に記載の単離されたモノクローナル抗体またはその抗原結合部分、請求項8に記載の核酸分子、請求項9に記載の発現ベクター、または請求項10に記載の宿主細胞と、薬学的に許容され得る担体とを含む、医薬組成物。
- 癌の治療を必要とする対象における癌の治療に使用するための、請求項11に記載の医薬組成物。
- 前記癌が、腎臓癌、骨髄異形成症候群、皮膚T細胞リンパ腫、鼻咽頭癌、エプスタインバーウイルス誘発性癌、ホジキンリンパ腫(HL)、非ホジキンリンパ腫(NHL)、びまん性大細胞型B細胞リンパ腫、濾胞性リンパ腫、Bリンパ性白血病、バーキットリンパ腫、多発性骨髄腫、ワルデンシュトレームマクログロブリン血症、胸腺癌、膠芽腫、脳癌、骨肉腫、メラノーマ、卵巣癌、腎細胞癌、乳癌、頭頸部扁平上皮癌、大腸癌、マントル細胞リンパ腫、前立腺腺癌、大腸腺癌、中枢神経系のリンパ腫、および非小細胞肺癌からなる群から選択される固形癌または血液癌である、請求項12に記載の使用するための医薬組成物。
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202111191860.4A CN113754769B (zh) | 2021-10-13 | 2021-10-13 | 靶向cd70的抗体及其制备和用途 |
CN202111191860.4 | 2021-10-13 |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2023058415A JP2023058415A (ja) | 2023-04-25 |
JP7355976B2 true JP7355976B2 (ja) | 2023-10-04 |
Family
ID=78799354
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2022015259A Active JP7355976B2 (ja) | 2021-10-13 | 2022-02-02 | Cd70と結合する抗体、その調製および使用 |
Country Status (5)
Country | Link |
---|---|
US (1) | US11613584B1 (ja) |
EP (1) | EP4166571A1 (ja) |
JP (1) | JP7355976B2 (ja) |
CN (1) | CN113754769B (ja) |
WO (1) | WO2023061063A1 (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN113754769B (zh) * | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd70的抗体及其制备和用途 |
CN118126184A (zh) * | 2022-01-19 | 2024-06-04 | 上海恒润达生生物科技股份有限公司 | 抗cd70纳米抗体及其用途 |
WO2024040195A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008538292A (ja) | 2005-04-19 | 2008-10-23 | シアトル ジェネティックス, インコーポレイテッド | ヒト化抗cd70結合剤およびその使用 |
JP2009509510A (ja) | 2005-09-26 | 2009-03-12 | メダレックス インコーポレーティッド | Cd70に対するヒトモノクローナル抗体 |
JP2011520782A (ja) | 2008-04-11 | 2011-07-21 | シアトル ジェネティックス, インコーポレイテッド | 膵臓癌、卵巣癌、および他の癌の検出および処置 |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4475196A (en) | 1981-03-06 | 1984-10-02 | Zor Clair G | Instrument for locating faults in aircraft passenger reading light and attendant call control system |
US4447233A (en) | 1981-04-10 | 1984-05-08 | Parker-Hannifin Corporation | Medication infusion pump |
US4439196A (en) | 1982-03-18 | 1984-03-27 | Merck & Co., Inc. | Osmotic drug delivery system |
US4447224A (en) | 1982-09-20 | 1984-05-08 | Infusaid Corporation | Variable flow implantable infusion apparatus |
US4487603A (en) | 1982-11-26 | 1984-12-11 | Cordis Corporation | Implantable microinfusion pump system |
US4486194A (en) | 1983-06-08 | 1984-12-04 | James Ferrara | Therapeutic device for administering medicaments through the skin |
US4596556A (en) | 1985-03-25 | 1986-06-24 | Bioject, Inc. | Hypodermic injection apparatus |
US4941880A (en) | 1987-06-19 | 1990-07-17 | Bioject, Inc. | Pre-filled ampule and non-invasive hypodermic injection device assembly |
US4790824A (en) | 1987-06-19 | 1988-12-13 | Bioject, Inc. | Non-invasive hypodermic injection device |
US5064413A (en) | 1989-11-09 | 1991-11-12 | Bioject, Inc. | Needleless hypodermic injection device |
US5312335A (en) | 1989-11-09 | 1994-05-17 | Bioject Inc. | Needleless hypodermic injection device |
US5383851A (en) | 1992-07-24 | 1995-01-24 | Bioject Inc. | Needleless hypodermic injection device |
US20120294863A1 (en) * | 2004-10-15 | 2012-11-22 | Seattle Genetics, Inc. | Anti-CD70 Antibody and Its Use for the Treatment and Prevention of Cancer and Immune Disorders |
CN101605906A (zh) * | 2006-12-14 | 2009-12-16 | 梅达雷克斯公司 | 结合cd70的人类抗体及其用途 |
MX2009006277A (es) * | 2006-12-14 | 2009-07-24 | Medarex Inc | Anticuerpos humanos que se enlazan a cd70 y usos de los mismos. |
PL2686347T3 (pl) * | 2011-03-16 | 2018-10-31 | Argenx Bvba | Przeciwciała przeciwko CD70 |
EP2758437B1 (en) * | 2011-09-22 | 2020-06-03 | Amgen Inc. | Cd27l antigen binding proteins |
EP2861262B1 (en) * | 2012-06-19 | 2018-11-28 | Ambrx, Inc. | Anti-cd70 antibody drug conjugates |
CA2921639A1 (en) * | 2013-09-05 | 2015-03-12 | Aduro Biotech Holdings, Europe B.V. | Cd70-binding peptides and method, process and use relating thereto |
CN106146670B (zh) | 2015-04-24 | 2019-01-15 | 宜明昂科生物医药技术(上海)有限公司 | 一种新的重组双功能融合蛋白及其制备和应用 |
JP2017141172A (ja) * | 2016-02-08 | 2017-08-17 | 日本全薬工業株式会社 | 抗イヌcd70モノクローナル抗体 |
CN111936519A (zh) * | 2018-02-01 | 2020-11-13 | 辉瑞公司 | 对cd70具有特异性的抗体及其用途 |
CN113754769B (zh) * | 2021-10-13 | 2023-06-06 | 宜明昂科生物医药技术(上海)股份有限公司 | 靶向cd70的抗体及其制备和用途 |
-
2021
- 2021-10-13 CN CN202111191860.4A patent/CN113754769B/zh active Active
-
2022
- 2022-02-02 JP JP2022015259A patent/JP7355976B2/ja active Active
- 2022-02-08 EP EP22155661.6A patent/EP4166571A1/en active Pending
- 2022-03-03 US US17/685,501 patent/US11613584B1/en active Active
- 2022-08-25 WO PCT/CN2022/114942 patent/WO2023061063A1/zh unknown
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2008538292A (ja) | 2005-04-19 | 2008-10-23 | シアトル ジェネティックス, インコーポレイテッド | ヒト化抗cd70結合剤およびその使用 |
JP2009509510A (ja) | 2005-09-26 | 2009-03-12 | メダレックス インコーポレーティッド | Cd70に対するヒトモノクローナル抗体 |
JP2011520782A (ja) | 2008-04-11 | 2011-07-21 | シアトル ジェネティックス, インコーポレイテッド | 膵臓癌、卵巣癌、および他の癌の検出および処置 |
Also Published As
Publication number | Publication date |
---|---|
CN113754769B (zh) | 2023-06-06 |
US20230112123A1 (en) | 2023-04-13 |
CN113754769A (zh) | 2021-12-07 |
US11613584B1 (en) | 2023-03-28 |
WO2023061063A1 (zh) | 2023-04-20 |
EP4166571A1 (en) | 2023-04-19 |
JP2023058415A (ja) | 2023-04-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2021136308A1 (en) | Antibodies binding bcma and uses thereof | |
KR101411165B1 (ko) | 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날항체 | |
JP7355976B2 (ja) | Cd70と結合する抗体、その調製および使用 | |
JP7355977B2 (ja) | Cd24に結合する抗体、その調製および使用 | |
US10946092B1 (en) | Antibodies binding LAG3 and methods of treatment using them | |
WO2021027662A1 (en) | Antibodies binding vista and uses thereof | |
WO2021170020A1 (en) | Antibodies binding il4r and uses thereof | |
CN112236455A (zh) | 结合pd-1的抗体及其用途 | |
US11718674B2 (en) | Antibodies binding PD-L1 and uses thereof | |
CA3097062A1 (en) | Antibodies binding pd-1 and uses thereof | |
WO2023202672A1 (en) | Antibodies targeting sirp-alpha and uses thereof | |
WO2021136323A1 (en) | Antibodies binding bcma and uses thereof | |
US20230382995A1 (en) | Molecules binding pd-l1 and uses thereof | |
WO2022257279A1 (en) | Antibodies binding tigit and uses thereof | |
US20220195043A1 (en) | Antibodies binding human and monkey cd3 and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220404 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230322 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230518 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20230815 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20230821 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 7355976 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |